Xenetic Biosciences, Inc.
XBIO · XNASCIK 1534525fmd_1KJYGBZSMHNN8GQBVMB5F9ES4W制造业 · 医药制剂模板: 标准
覆盖范围: 2010年12月01日 至 2026年9月30日，共 65 个期间
| 项目 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| 营业总收入 | 3 | 8 | 0 | 0 | 0 | 1 | 2 | 3 | 3 | 3 |
| 营业成本 | – | – | – | – | – | – | – | – | – | – |
| 净利息收入 | – | (0) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 毛利润 | – | – | – | – | – | – | – | – | – | – |
| 研发费用 | 44 | 4 | 3 | 5 | 2 | 3 | 5 | 3 | 3 | 3 |
| 营业费用合计 | – | – | 7 | 13 | 14 | 7 | 8 | 7 | 7 | 6 |
| 营业利润 | (47) | (4) | (7) | (13) | (14) | (6) | (7) | (5) | (4) | (3) |
| 利息费用 | 1 | 0 | – | – | – | – | – | – | – | – |
| 利息及投资收益 | – | – | – | – | – | – | – | – | – | – |
| 其他营业外收入（支出） | (7) | (0) | (0) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 税前利润 | – | – | – | – | – | – | – | – | – | – |
| 所得税费用 | 0 | 0 | 0 | 0 | (3) | 0 | 0 | 0 | 0 | 0 |
| 持续经营净利润 | – | – | – | – | – | – | – | – | – | – |
| 净利润 | (54) | (4) | (7) | (13) | (11) | (6) | (7) | (4) | (4) | (3) |
| 归属于普通股股东的净利润 | (58) | (4) | (7) | (18) | (11) | – | – | – | – | – |